MX2008016493A - Metodo para la deteccion de diagnostico de cancer que implica cebadores y sondas para la deteccion especifica del marcador mage-3. - Google Patents
Metodo para la deteccion de diagnostico de cancer que implica cebadores y sondas para la deteccion especifica del marcador mage-3.Info
- Publication number
- MX2008016493A MX2008016493A MX2008016493A MX2008016493A MX2008016493A MX 2008016493 A MX2008016493 A MX 2008016493A MX 2008016493 A MX2008016493 A MX 2008016493A MX 2008016493 A MX2008016493 A MX 2008016493A MX 2008016493 A MX2008016493 A MX 2008016493A
- Authority
- MX
- Mexico
- Prior art keywords
- detection
- mage
- probes
- marker
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Manufacturing & Machinery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a cebadores y sondas específicos de MAGE-A3 para utilizar equipos y métodos de diagnóstico nuevos. La presente invención se refiere además al tratamiento inmunoterapéutico de poblaciones específicas de pacientes con cáncer, que padecen de tumores que expresan MAGE-A3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0612342.6A GB0612342D0 (en) | 2006-06-21 | 2006-06-21 | Method |
PCT/EP2007/056219 WO2007147876A2 (en) | 2006-06-21 | 2007-06-21 | Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage- a3 -marker |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2008016493A true MX2008016493A (es) | 2009-05-21 |
Family
ID=36803668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2008016493A MX2008016493A (es) | 2006-06-21 | 2007-06-21 | Metodo para la deteccion de diagnostico de cancer que implica cebadores y sondas para la deteccion especifica del marcador mage-3. |
Country Status (28)
Country | Link |
---|---|
US (1) | US8936919B2 (es) |
EP (1) | EP2041308B1 (es) |
JP (2) | JP2009540812A (es) |
KR (1) | KR101455589B1 (es) |
CN (1) | CN101506383B (es) |
AU (1) | AU2007263019B2 (es) |
BR (1) | BRPI0713599A2 (es) |
CA (1) | CA2656909A1 (es) |
CO (1) | CO6140072A2 (es) |
CY (1) | CY1113290T1 (es) |
DK (1) | DK2041308T3 (es) |
EA (1) | EA016347B1 (es) |
ES (1) | ES2389513T3 (es) |
GB (1) | GB0612342D0 (es) |
HK (1) | HK1127627A1 (es) |
HR (1) | HRP20120761T1 (es) |
IL (1) | IL195975A (es) |
MA (1) | MA30565B1 (es) |
MX (1) | MX2008016493A (es) |
MY (1) | MY147511A (es) |
NO (1) | NO20085290L (es) |
NZ (1) | NZ573809A (es) |
PL (1) | PL2041308T3 (es) |
PT (1) | PT2041308E (es) |
SI (1) | SI2041308T1 (es) |
UA (1) | UA95956C2 (es) |
WO (1) | WO2007147876A2 (es) |
ZA (1) | ZA200810695B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ583796A (en) | 2007-09-17 | 2011-12-22 | Oncomethylome Sciences Sa | Improved detection of mage-a expression |
BR112013001637A2 (pt) * | 2010-07-22 | 2016-05-24 | Glaxosmithkline Biolog Sa | proteína ligadora de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para produção de proteína ligadora de antígeno, e para detectar mage-a3 e/ou mage-a6 em tecido de humano fixado com formalina e infiltrado em parafina. |
CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5612201A (en) * | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
IL106610A0 (en) * | 1992-08-07 | 1993-12-08 | Cytel Corp | Hla binding peptides and their uses |
CA2184482A1 (en) * | 1994-03-01 | 1995-09-08 | Etienne De Plaen | Determination of cancerous conditions by mage gene expression |
US5985571A (en) | 1998-02-04 | 1999-11-16 | Ludwig Institute For Cancer Research | Method for determining multiple myeloma by assaying for expression of mage genes |
BR9907691B1 (pt) * | 1998-02-05 | 2011-05-31 | derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. | |
WO2000020445A2 (en) * | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
JP3603138B2 (ja) * | 2000-02-18 | 2004-12-22 | 独立行政法人理化学研究所 | 細胞死抑制タンパク質 |
US6358679B1 (en) * | 2000-08-24 | 2002-03-19 | Pe Corporation (Ny) | Methods for external controls for nucleic acid amplification |
US6635425B2 (en) * | 2001-01-05 | 2003-10-21 | Molecular Staging, Inc. | 5′-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms |
WO2003045427A2 (en) * | 2001-11-29 | 2003-06-05 | Dandrit Biotech A/S | Pharmaceutical composition for inducing an immune response in a human or animal |
DK2284266T3 (da) | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
AU2003290925A1 (en) * | 2002-11-14 | 2004-06-15 | John Wayne Cancer Institute | Detection of micro metastasis of melanoma and breast cancer in paraffin-embedded tumor draining lymph nodes by multimaker quantitative rt-pcr |
GB0409940D0 (en) * | 2004-05-04 | 2004-06-09 | Glaxosmithkline Biolog Sa | Vaccine |
US20070231822A1 (en) * | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
-
2006
- 2006-06-21 GB GBGB0612342.6A patent/GB0612342D0/en not_active Ceased
-
2007
- 2007-06-21 AU AU2007263019A patent/AU2007263019B2/en not_active Ceased
- 2007-06-21 NZ NZ573809A patent/NZ573809A/en not_active IP Right Cessation
- 2007-06-21 CN CN2007800309371A patent/CN101506383B/zh not_active Expired - Fee Related
- 2007-06-21 BR BRPI0713599-8A patent/BRPI0713599A2/pt not_active IP Right Cessation
- 2007-06-21 UA UAA200814634A patent/UA95956C2/uk unknown
- 2007-06-21 WO PCT/EP2007/056219 patent/WO2007147876A2/en active Application Filing
- 2007-06-21 MY MYPI20085210A patent/MY147511A/en unknown
- 2007-06-21 EA EA200802356A patent/EA016347B1/ru not_active IP Right Cessation
- 2007-06-21 DK DK07786793.5T patent/DK2041308T3/da active
- 2007-06-21 SI SI200731011T patent/SI2041308T1/sl unknown
- 2007-06-21 PL PL07786793T patent/PL2041308T3/pl unknown
- 2007-06-21 ES ES07786793T patent/ES2389513T3/es active Active
- 2007-06-21 US US12/305,742 patent/US8936919B2/en not_active Expired - Fee Related
- 2007-06-21 CA CA002656909A patent/CA2656909A1/en not_active Abandoned
- 2007-06-21 KR KR1020097001326A patent/KR101455589B1/ko not_active IP Right Cessation
- 2007-06-21 MX MX2008016493A patent/MX2008016493A/es active IP Right Grant
- 2007-06-21 JP JP2009515886A patent/JP2009540812A/ja active Pending
- 2007-06-21 PT PT07786793T patent/PT2041308E/pt unknown
- 2007-06-21 EP EP07786793A patent/EP2041308B1/en active Active
-
2008
- 2008-12-16 IL IL195975A patent/IL195975A/en not_active IP Right Cessation
- 2008-12-18 ZA ZA2008/10695A patent/ZA200810695B/en unknown
- 2008-12-18 NO NO20085290A patent/NO20085290L/no not_active Application Discontinuation
- 2008-12-19 MA MA31490A patent/MA30565B1/fr unknown
- 2008-12-24 CO CO08136749A patent/CO6140072A2/es unknown
-
2009
- 2009-07-20 HK HK09106609.1A patent/HK1127627A1/xx not_active IP Right Cessation
-
2012
- 2012-09-26 HR HRP20120761TT patent/HRP20120761T1/hr unknown
- 2012-10-02 CY CY20121100908T patent/CY1113290T1/el unknown
- 2012-11-08 JP JP2012245934A patent/JP5705191B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008298744A8 (en) | MiRNA expression in human peripheral blood microvesicles and uses thereof | |
MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
WO2007140958A3 (en) | Method for identifying whether a patient will be responder or not to immunotherapy | |
MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
EP3683320A3 (en) | Mirna fingerprint in the diagnosis of lung cancer | |
WO2012006589A3 (en) | Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling | |
WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
EP2179037A4 (en) | DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES | |
WO2007081680A3 (en) | Microrna expression abnormalities in pancreatic endocrine and acinar tumors | |
MX2010000405A (es) | Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos. | |
AU2011260390A8 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
WO2012068383A3 (en) | ncRNA AND USES THEREOF | |
MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
MX340724B (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. | |
WO2010091049A3 (en) | Diagnosis and treatment of cancer | |
MX2013011431A (es) | Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico. | |
MX2009013649A (es) | Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma. | |
MX2015000008A (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
WO2007123722A3 (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
WO2010101793A3 (en) | Methods and compositions for the diagnosis, prognosis and treatment of cancer | |
WO2011093675A3 (ko) | 혈액으로부터 직접 폐암 진단 및 폐암의 서브타입 진단이 가능한 마커를 선별하는 시스템 생물학적 방법 및 이로부터 선별된 혈액으로부터 직접 폐암 진단 및 폐암 서브타입 진단이 가능한 마커 | |
IN2012DN01979A (es) | ||
WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
SG179129A1 (en) | Method for identifying whether a patient will be responder or not to immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |